First Approvals Received for Start of Phase 3 FSGS Trial

First ethics and regulatory approval received for ACTION3 Phase 3 FSGS study in Australia >50% sites selected globally to conduct study Part 1 to first interim analysis point Recruitment and screening expected to commence this quarter MELBOURNE, Australia, 21 October 2021: Dimerix Limited (ASX: DXB), a biopharmaceutical company with multiple near-term Phase 3 clinical studies in inflammatory disea